University Hospital for Tumours of Zagreb Trials

Go back to University Hospital for Tumours of Zagreb page

NCTID: NCT02562443

Title: Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA 
Study Summary: The study’s primary objective <math display="block">in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)</math>, is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician’s Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk. 
Sponsor: Onconova Therapeutics, Inc. 
Intervention: rigosertib 
Start Date: 2015-12-02 
Last Updated: 2022-09-26 
Number of Patients: 372 
Recruitment Status: TERMINATED 
Condition: Myelodysplastic Syndrome 

NCTID: NCT04736706

Title: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) 
Study Summary: The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).  The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants. 
Sponsor: Merck Sharp & Dohme LLC 
Intervention: Pembrolizumab 
Start Date: 2021-04-14 
Last Updated: 2023-12-04 
Number of Patients: 1653 
Recruitment Status: RECRUITING 
Condition: Carcinoma, Renal Cell 

NCTID: NCT01339260

Title: An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting 
Study Summary: NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy. 
Sponsor: Helsinn Healthcare SA 
Intervention: Netupitant and Palonosetron 
Start Date: 2011-04 
Last Updated: 2014-11-26 
Number of Patients: 1455 
Recruitment Status: COMPLETED 
Condition: Chemotherapy-Induced Nausea and Vomiting 

NCTID: NCT00989131

Title: Study of Paclitaxel in Patients With Ovarian Cancer 
Study Summary: RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical® does not contain Cremophor EL, hypersensitivity reactions can be expected to be less.  PURPOSE: To study the efficay and safety of two different formulations of paclitaxel, Paclical® and Taxol®. 
Sponsor: Oasmia Pharmaceutical AB 
Intervention: Paclical® 
Start Date: 2009-02 
Last Updated: 2014-02-04 
Number of Patients: 789 
Recruitment Status: COMPLETED 
Condition: Epithelial Ovarian Cancer 

NCTID: NCT02668653

Title: Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) 
Study Summary: Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.  Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).  Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy. 
Sponsor: Daiichi Sankyo, Inc. 
Intervention: Chemotherapy 
Start Date: 2016-09-01 
Last Updated: 2023-11-18 
Number of Patients: 539 
Recruitment Status: COMPLETED 
Condition: Acute Myeloid Leukemia 

NCTID: NCT04700124

Title: Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 
Study Summary: The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy <math display="block">gemcitabine plus cisplatin</math> and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B). 
Sponsor: Merck Sharp & Dohme LLC 
Intervention: Pembrolizumab 
Start Date: 2021-04-21 
Last Updated: 2023-11-18 
Number of Patients: 784 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Muscle Invasive Bladder Cancer